TABLE 1.
Basic recipient and donor characteristics.
| 20-year survivors | Total (n = 248) | Group 1 (n = 96) | Group 2 (n = 152) | p-value | |||
|---|---|---|---|---|---|---|---|
| n | n | n | |||||
| First transplant | 248 | 227 (91.5%) | 96 | 92 (95.8%) | 152 | 135 (88%) | |
| Second transplant | 21 (8.5%) | 4 (4.2%) | 17 (11.2%) | 0.089 | |||
| Female KTR | 248 | 92 (37.1%) | 96 | 26 (27.1%) | 152 | 66 (43.4%) | 0.014* |
| KTR age (years) a | 248 | 39.9 (17.3–68.8) | 96 | 38.1 (17.6–67.3) | 152 | 40.3 (17.3–68.8) | 0.663 |
| Cause of ESKD b | 248 | 96 | 152 | ||||
| GN c | 89 (35.9%) | 28 (29.2%) | 61 (40.1%) | 0.106 | |||
| Uropathy d | 45 (18.1%) | 16 (16.7%) | 29 (19.1%) | 0.756 | |||
| Diabetes mellitus | 5 (2.0%) | 2 (2.1%) | 3 (2.0%) | 1.0 | |||
| Hypertension | 4 (1.6%) | 1 (1.0%) | 3 (2.0%) | 1.0 | |||
| ADPKD e | 30 (12.1%) | 13 (13.5%) | 17 (11.2%) | 0.723 | |||
| Alport syndrome | 9 (3.6%) | 6 (6.3%) | 3 (2.0%) | 0.093 | |||
| Other | 28 (11.3%) | 12 (12.5%) | 16 (10.5%) | 0.785 | |||
| Unknown | 38 (15.3%) | 18 (18.8%) | 20 (13.2%) | 0.313 | |||
| Pretransplant dialysis | 248 | 96 | 152 | ||||
| preemptive transplantation | 6 (2.4%) | 2 (2.1%) | 4 (2.6%) | 1.0 | |||
| HD f (only HD or PD/HD) | 193 (77.8%) | 77 (80.2%) | 116 (76.3%) | ||||
| only PD g | 49 (19.8%) | 17 (17.7%) | 32 (21.1%) | 0.615 | |||
| pretransplant dialysis (months) h | 221 | 25 (2–164) | 90 | 22 (2–120) | 131 | 28 (3–164) | 0.047* |
| Total HLA Mismatch (A, B, DR) | 248 | 3 (0–6) | 96 | 3 (1–6) | 152 | 3 (0–6) | 0.343 |
| Total PIRCHE-II (A, B, DR) | 38.23 (0–111.63) | 38.99 (14.07–97.72) | 37.92 (0–111.63) | 0.663 | |||
| 0–2 HLA Mismatches | 48 (19.4%) | 15 (15.6%) | 33 (21.7%) | ||||
| 3–6 HLA Mismatches | 200 (80.6%) | 81 (84.4%) | 119 (78.3%) | 0.309 | |||
| HLA A Mismatch | 1 (0–2) | 1 (0–2) | 1 (0–2) | 0.07 | |||
| HLA B Mismatch | 1 (0–2) | 1 (0–2) | 1 (0–2) | 0.712 | |||
| PIRCHE-II (A, B) | 26.35 (0–85.74) | 28.13 (4.31–79.97) | 25.24 (0–85.74) | 0.665 | |||
| HLA DR Mismatch | 1 (0–2) | 1 (0–2) | 1 (0–2) | 0.813 | |||
| PIRCHE-II (DR) | 8.06 (0–58.58) | 6.94 (0–38.70) | 9.44 (0–58.58) | 0.221 | |||
| Donor characteristics | |||||||
| Living donor transplant | 248 | 14 (5.6%) | 96 | 3 (3.1%) | 152 | 11 (7.2%) | 0.278 |
| Donation after cardiac death | 248 | 28 (11.3%) | 96 | 6 (6.3%) | 152 | 22 (14.5%) | 0.063 |
| Donor age (years) | 247 | 32 (3–72) | 96 | 25 (3–63) | 151 | 37 (3–72) | 0.001** |
| Male donor | 245 | 167 (68.2%) | 94 | 65 (69.1%) | 151 | 102 (67.5%) | 0.904 |
| CIT (hours) i | 242 | 14 (1–34) | 96 | 14.25 (1.5–34) | 146 | 13.5 (1–32.5) | 0.307 |
| Era of transplantation | 248 | 96 | 152 | ||||
| 1981–1989 | 92 (37.1%) | 41 (42.7%) | 51 (33.6%) | ||||
| 1990–1999 | 156 (62.9%) | 55 (57.3%) | 101 (66.4%) | 0.187 | |||
a
At the date of transplantation.
b
End stage kidney disease.
c
Glomerulonephritis, incl. vasculitis, systemic lupus erythematosus, and suspected chronic GN.
d
Incl. congenital anomalies of the kidney and urinary tract, CAKUT.
e
Autosomal dominant polycystic kidney disease.
f
Hemodialysis (only HD or both, PD and HD).
g
Peritoneal dialysis.
h
Only KTRs with the first transplant.
i
Cold ischemia time.